20Mg 4.5Ml Qarziba Dinutuximab Injection

Qarziba (Dinutuximab beta) 20 mg/4.5 mL injection is a monoclonal antibody used to treat high-risk neuroblastoma in patients aged 12 months and older. It is indicated for those who have previously received induction chemotherapy with at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as for patients with relapsed or refractory neuroblastoma, with or without residual disease. Prior to treatment of relapsed neuroblastoma, any actively progressing disease should be stabilized by other suitable measures.